Stephen Sykes

Profile picture
Associate Professor of Pediatrics, Hematology and Oncology
Researcher, Hematology and Oncology

phone: (314) 454-6018


  • AA, Ulster County Community College1997
  • BS, Mount Allison University2000
  • PhD, University of Pennsylvannia2007


  • Post-doctoral Fellowship, Harvard Medical School - Brigham and Women's Hospital2008 - 2009
  • Post-doctoral Fellowship, Harvard Medical School - Massachusetts General Hospital2009 - 2012

Honors and Awards

  • Mount Allison University Entrance Scholarship1997 - 1998
  • Academic All-Canadian - Basketball2000
  • Monica Shander Award for Outstanding Pre-Doctoral Research (Wistar Institute)2006
  • International Society of Experimental Hematology (ISEH) Eugene Goldwasser Fellowship2011 - 2012
  • American Society of Hematology (ASH) Junior Scholar Award2014 - 2016
  • American Cancer Society Research Scholar Award2019 - 2022

Recent Publications view all (44)

  1. The ERK2-DBP domain opposes pathogenesis of a mouse JAK2V617F-driven myeloproliferative neoplasm. Blood. 2022;140(4):359-373. PMID:35436326 
  2. TET2 and DNMT3A Mutations Exert Divergent Effects on DNA Repair and Sensitivity of Leukemia Cells to PARP Inhibitors. Cancer Res. 2021. PMID:34215619 
  3. ATF3 coordinates serine and nucleotide metabolism to drive cell cycle progression in acute myeloid leukemia. Mol Cell. 2021;81(13):2752-2764.e6. PMID:34081901 
  4. The SAGA complex regulates early steps in transcription via its deubiquitylase module subunit USP22. EMBO J. 2021;e102509. PMID:34155658 
  5. BRCA1 Mutational Complementation Induces Synthetic Viability. Mol Cell. 2020;78(5):951-959.e6. PMCID:PMC7418109  PMID:32359443 
  6. IL-27 receptor-regulated stress myelopoiesis drives abdominal aortic aneurysm development. Nat Commun. 2019;10(1):5046. PMCID:PMC6834661  PMID:31695038 
  7. Flow Cytometric Analysis of Mitochondrial Reactive Oxygen Species in Murine Hematopoietic Stem and Progenitor Cells and MLL-AF9 Driven Leukemia. J Vis Exp. 2019;(151). PMCID:PMC7239511  PMID:31545325 
  8. NCAM1 supports therapy resistance and LSC function in AML. Blood. 2019;133(21):2247-2248. PMID:31122937 
  9. BRCA1 Mutation-Specific Responses to 53BP1 Loss-Induced Homologous Recombination and PARP Inhibitor Resistance. Cell Rep. 2018;25(5):1384. PMCID:PMC6296467  PMID:30380426 
  10. RET-mediated autophagy suppression as targetable co-dependence in acute myeloid leukemia. Leukemia. 2018;32(10):2189-2202. PMID:29654265 
  11. The -2518 A/G polymorphism of the monocyte chemoattractant protein-1 as a candidate genetic predisposition factor for secondary myelofibrosis and biomarker of disease severity. Leukemia. 2018;32(10):2266-2270. PMCID:PMC6170394  PMID:29568096 
  12. BRCA1 Mutation-Specific Responses to 53BP1 Loss-Induced Homologous Recombination and PARP Inhibitor Resistance. Cell Rep. 2018;24(13):3513-3527.e7. PMCID:PMC6219632  PMID:30257212 
  13. Tyrosine kinase inhibitor-induced defects in DNA repair sensitize FLT3(ITD)-positive leukemia cells to PARP1 inhibitors. Blood. 2018;132(1):67-77. PMCID:PMC6034642  PMID:29784639 
  14. Protein Kinase C Epsilon Is a Key Regulator of Mitochondrial Redox Homeostasis in Acute Myeloid Leukemia. Clin Cancer Res. 2018;24(3):608-618. PMCID:PMC5796864  PMID:29127121 
  15. MLL-AF9 leukemias are sensitive to PARP1 inhibitors combined with cytotoxic drugs. Blood Adv. 2017;1(19):1467-1472. PMCID:PMC5728460  PMID:29296788 
  16. Gene expression and mutation-guided synthetic lethality eradicates proliferating and quiescent leukemia cells. J Clin Invest. 2017;127(6):2392-2406. PMCID:PMC5451241  PMID:28481221 
  17. JUN is a key transcriptional regulator of the unfolded protein response in acute myeloid leukemia. Leukemia. 2017;31(5):1196-1205. PMCID:PMC5473421  PMID:27840425 
  18. A rare DNA contact mutation in cancer confers p53 gain-of-function and tumor cell survival via TNFAIP8 induction. Mol Oncol. 2016;10(8):1207-20. PMCID:PMC5423199  PMID:27341992 
  19. The identity crisis of Hif-1α in HSC biology. Blood. 2016;127(23):2782-4. PMID:27282941 
  20. Clonal evolution of preleukemic hematopoietic stem cells in acute myeloid leukemia. Exp Hematol. 2015;43(12):989-92. PMCID:PMC5492948  PMID:26455528 
  21. PKCε as a novel promoter of skeletal muscle differentiation and regeneration. Exp Cell Res. 2015;339(1):10-9. PMCID:PMC5130411  PMID:26431586 
  22. mTOR kinase inhibitors promote antibody class switching via mTORC2 inhibition. Proc Natl Acad Sci U S A. 2014;111(47):E5076-85. PMCID:PMC4250172  PMID:25385646 
  23. Transmembrane Inhibitor of RICTOR/mTORC2 in Hematopoietic Progenitors. Stem Cell Reports. 2014;3(5):832-40. PMCID:PMC4235746  PMID:25418727 
  24. Inhibiting stromal cell heparan sulfate synthesis improves stem cell mobilization and enables engraftment without cytotoxic conditioning. Blood. 2014;124(19):2937-47. PMCID:PMC4224192  PMID:25202142 
  25. Requirement for CDK6 in MLL-rearranged acute myeloid leukemia. Blood. 2014;124(1):13-23. PMCID:PMC4190617  PMID:24764564 
  26. Proplatelet generation in the mouse requires PKCε-dependent RhoA inhibition. Blood. 2013;122(7):1305-11. PMCID:PMC3952532  PMID:23838351 
  27. Modeling human hematopoietic stem cell biology in the mouse. Semin Hematol. 2013;50(2):92-100. PMCID:PMC3826087  PMID:24216169 
  28. CDX2-driven leukemogenesis involves KLF4 repression and deregulated PPARγ signaling. J Clin Invest. 2013;123(1):299-314. PMCID:PMC3533294  PMID:23202735 
  29. mTOR complex 1 plays critical roles in hematopoiesis and Pten-loss-evoked leukemogenesis. Cell Stem Cell. 2012;11(3):429-39. PMCID:PMC3743253  PMID:22958934 
  30. Diabetes impairs hematopoietic stem cell mobilization by altering niche function. Sci Transl Med. 2011;3(104):104ra101. PMCID:PMC3754876  PMID:21998408 
  31. Differential niche and Wnt requirements during acute myeloid leukemia progression. Blood. 2011;118(10):2849-56. PMCID:PMC3172801  PMID:21765021 
  32. AKT/FOXO signaling enforces reversible differentiation blockade in myeloid leukemias. Cell. 2011;146(5):697-708. PMCID:PMC3826540  PMID:21884932 
  33. Crosstalk between NOTCH and AKT signaling during murine megakaryocyte lineage specification. Blood. 2011;118(5):1264-73. PMCID:PMC3152494  PMID:21653327 
  34. Deacetylation of the DNA-binding domain regulates p53-mediated apoptosis. J Biol Chem. 2011;286(6):4264-70. PMCID:PMC3039376  PMID:21148320 
  35. Hematopoietic stem cell defects in mice with deficiency of Fancd2 or Usp1. Stem Cells. 2010;28(7):1186-95. PMCID:PMC2910804  PMID:20506303 
  36. The Apc(min) mouse has altered hematopoietic stem cell function and provides a model for MPD/MDS. Blood. 2010;115(17):3489-97. PMCID:PMC2867262  PMID:20197553 
  37. Acetylation of the DNA binding domain regulates transcription-independent apoptosis by p53. J Biol Chem. 2009;284(30):20197-205. PMCID:PMC2740446  PMID:19494119 
  38. The p53 family and programmed cell death. Oncogene. 2008;27(50):6507-21. PMCID:PMC2657599  PMID:18955976 
  39. The putative cancer stem cell marker USP22 is a subunit of the human SAGA complex required for activated transcription and cell-cycle progression. Mol Cell. 2008;29(1):102-11. PMCID:PMC2254522  PMID:18206973 
  40. The ARF/oncogene pathway activates p53 acetylation within the DNA binding domain. Cell Cycle. 2007;6(11):1304-6. PMID:17534149 
  41. Acetylation of the p53 DNA-binding domain regulates apoptosis induction. Mol Cell. 2006;24(6):841-51. PMCID:PMC1766330  PMID:17189187 
  42. Menin induces apoptosis in murine embryonic fibroblasts. J Biol Chem. 2004;279(11):10685-91. PMCID:PMC2858560  PMID:14688275 
  43. Menin associates with FANCD2, a protein involved in repair of DNA damage. Cancer Res. 2003;63(14):4204-10. PMID:12874027 
  44. Fusion proteins of retinoid receptors antagonize TGF-beta-induced growth inhibition of lung epithelial cells. Oncogene. 2003;22(2):198-210. PMID:12527889 
Last updated: 11/14/2022
© 2022 by Washington University in St. Louis
One Brookings Drive, St. Louis, MO 63130